The KLHL12 Knockout A-549 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout population of human A-549 lung epithelial cells, with disruption of the KLHL12 gene. This loss-of-function model facilitates investigation of KLHL12, a substrate-specific adaptor of the BCR E3 ubiquitin ligase complex. The polyclonal format ensures heterogeneous gene disruption, avoiding clonal selection artifacts and enabling robust functional studies.
The A-549 cell line is a widely used human lung adenocarcinoma model with adherent epithelial morphology, derived from a 58-year-old Caucasian male. It serves as a type II pulmonary alveolar epithelial cell model, extensively applied in non-small cell lung cancer (NSCLC) research, drug metabolism studies, respiratory virus investigations, and cystic fibrosis research. Its well-characterized background provides a physiologically relevant context for gene function studies in lung epithelial biology.
KLHL12 functions as a substrate recognition subunit of the CUL3-RBX1 E3 ubiquitin ligase complex, directing ubiquitination and proteasomal degradation of key regulators. In Wnt signaling, it targets DVL2, modulating beta-catenin stabilization and TCF/LEF-mediated transcription. Additionally, KLHL12 ubiquitinates SEC31A to control COPII vesicle formation and ER-to-Golgi trafficking, and it regulates autophagy via TFE3 turnover. It responds to Wnt ligands and stress signals, interacting with CUL3, RBX1, SEC13, and substrates DVL2, SEC31A, and TFE3. Thus, KLHL12 integrates signal transduction, intracellular transport, and protein homeostasis.
In A-549 lung adenocarcinoma cells, KLHL12 disruption is particularly relevant for exploring NSCLC biology, where aberrant Wnt signaling promotes tumor progression and chemoresistance. Loss of KLHL12-mediated DVL2 degradation may activate Wnt, influencing proliferation, migration, and epithelial-mesenchymal transition. Altered COPII trafficking and autophagy can further affect secretory dynamics, stress responses, and drug sensitivity, offering a platform to study ubiquitin-dependent pathways in cancer.
This polyclonal knockout population supports diverse assays: TOP/FOP flash reporter for Wnt activity, co-immunoprecipitation for ubiquitination profiling, immunofluorescence for COPII trafficking, and western blotting for autophagy markers. Functional studies such as cell migration, proliferation, and drug sensitivity testing enable therapeutic target validation in NSCLC. By combining gene perturbation with cellular readouts, these cells advance mechanistic understanding of protein degradation networks. For further inquiries, please contact Ascent Research.
